Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer: A phase II trial of the EORTC-New Drug Development Group

European Journal of Cancer

Volumn 40, Issue 5, 2004, Pages 667-672

  Giaccone, G ^a   Smit, E F ^a   De Jonge, M ^b   Dansin, E ^c   Briasoulis, E ^d   Ardizzoni, A ^e   Douillard, J Y ^f   Spaeth, D ^g   Lacombe, D ^h   Baron, B ^h   Bachmann, P ⁱ   Fumoleau, P ^f  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CENTRE OSCAR LAMBRET   (France)

^d UNIVERSITY OF IOANNINA   (Greece)

^e UNIVERSITY OF GENOA   (Italy)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g CENTRE ALEXIS VAUTRIN   (France)

^h EORTC DATA CENTER   (Belgium)

ⁱ Baxter Oncology GmbH   (Germany)

Author keywords

Chemotherapy; Glufosfamide; Non small cell lung cancer; Phase II

Indexed keywords

ANTINEOPLASTIC AGENT; GLUFOSFAMIDE; IFOSFAMIDE; PLATINUM; UNCLASSIFIED DRUG;

ACIDOSIS; ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIURESIS; DOSE RESPONSE; DRUG ACTIVITY; ELECTROLYTE DISTURBANCE; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYDRATION; LUNG NON SMALL CELL CANCER; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEPHRON; NEPHROTOXICITY; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORAMIDE MUSTARDS; PROSPECTIVE STUDIES;

EID: 12144285603     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.10.027     Document Type: Article

References (11)

1. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer. a meta-analysis using updated data on individual patients from 52 randomised clinical trials Br. Med. J. 311:1995;899-909.
2. Schiller J.H., Harrington D., Belani C.P.et al. The Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:2002;92-98.
3. Shepherd F.A., Dancey J., Ramlau R.et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2000;2095-2103.
4. Fossella F.V., DeVore R., Kerr R.N.et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. 18:2000;2354-2362.
5. Huisman C., Smit E.F., Giaccone G., Postmus P.E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer. a review J. Clin. Oncol. 18:2000;3722-3730.
6. Pohl J., Bertram B., Hilgard P., Nowrousian M.R., Stuben J., Wiessler M. D-19575. a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport Cancer Chemother. Pharmacol. 35:1995;364-370.
7. Veyhl M., Wagner K., Volk C.et al. Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. Proc. Nat. Acad. Sci. USA. 95:1998;2914-2919.
8. Briasoulis E., Judson I., Pavlidis N.et al. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters. a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group J. Clin. Oncol. 18:2000;3535-3544.
9. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0 (https://webapps.ctep.nci.nih.gov/ctcv2/), 1999.
10. Fukuoka M., Yano S., Giaccone G.et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246.
11. Giaccone G. Lung cancer. clinical impact of novel treatment strategies Oncogene. 21:2002;6970-6981.